Health Breaking News: Link 257

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 257

 

The Role of Aid for Trade in Building the Capacity of Developing Country Firms to Meet Sustainability Standards 

UNPO: Promoting Culture and Supporting Human Rights for the Uyghur People, 19 October 2017 9:00-12:00 European Parliament room 4Q1 Brussels 

Human Rights Reader 424 

A Funder Looks for Scalable Tactics to Fight Poverty and Social Isolation Among the Elderly 

New DIB brings in big donors, provides biggest test of model to date 

Brazil: extreme inequality in numbers 

ABUSE ON COTTON FIELDS PERSISTS DESPITE CHANGE IN UZBEK POLICY 

Global services and support for children with developmental delays and disabilities: Bridging research and policy gaps 

Getting serious about financing the end of epidemics 

New global vector control response 2017-2030 now online 

Madagascar plague: WHO in huge release of antibiotics 

Africa and Asia lead in proportion of blind adults 

WHO, partners gear for world’s second largest oral cholera vaccination campaign in Cox’s Bazar 

MSF: A Fair Shot for Vaccine Affordability: Understanding and addressing the effects of patents on access to newer vaccines 

100 Women: Is child vaccination boosted by educating mothers? 

Nearly One-Third Of New Drugs Are No Better Than Older Drugs, And Some Are Worse 

Mechanism To Assess Trade Agreements Needed, UN Forum On Access To Medicines Hears 

New: latest framework for action by pharmaceutical companies on access to medicine 

MSF: Slow scale-up of newer MDR-TB drugs covers less than 5% in need 

How to Eradicate Rural Poverty, End Urban Malnutrition – A New Approach 

UNICEF warns of nutrition crisis affecting 165,000 children in Mali 

2017 Hunger Index shows SDG zero hunger goal under threat 

Fixing the Food System to Solve Humanity’s Greatest Challenges 

Tenfold increase in childhood and adolescent obesity in four decades: new study by Imperial College London and WHO 

WHO Establishes High-Level Commission On Noncommunicable Diseases 

Why Do Land Rights Matter to Communities and Companies? 

A radical change is needed for the health of the planet and the people 

Oxfam exposes ‘great abuse’ in EU’s approach to migration 

Want to ensure your research influences policy? Top advice from a Foreign Office insider 

10TH ECTMIH ANTWERP, BELGIUM October 16-20, 2017

How Can EU Trade Policy Ensure Equitable Access to Medicines?

High medicine prices is a key public health challenge in Europe and Trade policy – an exclusive EU competence can improve or exacerbate the situation. Free Trade and Investment agreements can make easier or harder for European governments to change existing policies to curb the costs of pharmaceuticals. Following a civil society dialogue meeting with EU Trade Commissioner Cecilia Malmström, the author is calling for policy between public health and trade goals on medicines, giving a priority to population health

By Zoltán Massay-Kosubek *

Policy Manager for Health Policy Coherence at the European Public Health Alliance (EPHA)

How Can EU Trade Policy Ensure Equitable Access to Medicines?

 

 6th October 2017 Civil Society Dialogue with Commissioner Cecilia Malmström on Trade and Sustainable Development

 

Policy coherence is needed between health and trade policies on medicines

The pharmaceutical sector is significant for both international trade and public spending. An OECD report[1] estimates that EU pharmaceutical spending amounted to around €190 billion in 2010, almost 1.5 % of gross domestic product (GDP).

The Doha Declaration[2] on the WTO Agreement on Trade-Related Aspects of IPRs (TRIPs)[3] and public health adopted on 14 November 2001 recognises concerns over the relationship between protection of Intellectual Property Rights (IPRs) and the impact on medicine prices. The EU’s global health strategy of 2010[4] states that the EU’s trade policy should ensure more effective use of the TRIPs – provisions to increase the affordability and accessibility of medicines.

The 32nd Session of the UN Human Rights Council adopted a resolution in July 2016 highlighting the correlation between patent-based monopolies or exclusivities and the challenges in accessing affordable medicines across the globe.

In November 2015, the UN Secretary-General Ban Ki-Moon launched a High-Level Panel on Access to Medicines (UN HLP) to “review and assess proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies.” The Panel collected contributions[5] from interested stakeholders and it was supported by an Expert Advisory Group consisting of 16 members, from the public and private sector, academia, professional and civil society organisations, serving in their private capacity. In September 2016, the UN HLP published its final report[6] which calls for public health assessments to be done as part of every free trade negotiation to assess the possible impact on public health and for the creation of public health patentability criteria. It also encourages the use of TRIPS flexibilities and calls on governments to create an enabling legal environment for issuing compulsory licenses. It states that the cost of R&D should be delinked from end prices to promote universal access and that new and additional models for financing and rewarding public health research and development should be implemented.

The EU is at crossroads – how sustainable is the EU Trade Policy?

The EU has considerable global trade power and it aims to put emphasis on the sustainable aspects of its trade policy. This is why EU free trade agreements (FTAs) systematically contain chapters dedicated to sustainable development. However, the glass is half empty: while the aim is good those chapters historically are limited to only two aspects: environmental and labour sustainability. This approach seems to be outdated especially now that health sustainability is key part of the Sustainable Development Goals (SDGs) and the EU trade policy simply cannot afford to neglect those health aspects. This is what I have stressed during the 6th October 2017 civil society dialogue meeting with Commissioner Malmström.

VIDEO 1 statement on the health sustainability of the EU Trade Policy

URL https://youtu.be/dMEVc05ElTI

 

Background – EU Trade Commissioner Malmström with civil society

As part of an ongoing process of Civil Society Dialogue on EU trade policy, Commissioner Malmström has presented current developments and had an exchange views with civil society organisations on Trade and Sustainable Development (TSD) on 6th October. The Commission is undertaking comprehensive discussions with the Council, EP and stakeholders with a view to improve implementation of TSD chapters in the EU’s FTAs. It follows the Commission’s recent reflection paper on harnessing globalisation, which underlined the EU’s commitment to a fair, international, rules-based order based on high standards, cooperation and strengthening of multilateral institutions. The Commission is committed to include TSD chapters in trade agreements to reflect the EU’s value-based trade agenda.

How can EU Trade Policy cement an insurmountable barrier to equitable access to medicines?

IPRs are crucial for research and innovation but if they are misused they can seriously compromise equitable access to medicines by keeping medicine prices at exorbitant high level without proper justification. High medicine prices are not only relevant for the Global South but also for Europe. In the EU, Sofosbuvir, a medicine used to treat Hepatitis C, is a real-life example of the challenge of high medicine prices in Europe. While the 12-weeks treatment course is priced at €41,680 to the French Social Security system, the Indian, generic version is sold at only €220.[7]

Equally, the fact that IPRs are protected in many of the EU’s current and future deals, shows a failure to recognise concerns regarding the impact IPRs have on medicine prices. IPR acts as an insurmountable barrier to equitable access to medicines, by granting monopolies to a given medicine, meaning that other, cheaper, generic versions of the same medicines cannot be placed on the market until the patent protection exists, which drives up prices. It is very difficult to change patent processes once they are locked into international trade agreements.

Closing our eyes does not solve the problem

In her answer, the Commissioner while confirmed her commitment to health, she preferred including health elements throughout the agreement, mentioning food safety as an example. However, this should not be used as an excuse not to have health elements in the sustainable development chapter. Sustainability cannot be reduced to environment and labour. If EU FTAs remain blind to the link between IPR and high medicine prices, EU trade policy will maintain the current, ineffective and costly R&D system rewarding new medicines with fixed-term patent related market- and data exclusivities. If health sustainability aspects are properly managed, EU trade policy can contribute to the creation of an R&D system that is driven by public health needs and delivers medicines that are universally accessible and affordable.

Video 2 Commissioner Malmström’s answer to my statement on health sustainability of EU Trade policy

URL  https://youtu.be/FAX0Xiu-IA8

 

Conclusions – business as usual is not an option anymore

If health sustainability aspects remains under the carpet, and EU trade policy will be limited to environment and labour aspects only, we do risk that FTAs will lock Europeans and their negotiating partners into a system which allows pharmaceutical companies to charge patients and health services exorbitant prices for medicines that bear no relation to their R&D costs, and fails to address priority health needs.

——————————————-

*Zoltán is Policy Manager for Health Policy Coherence at the European Public Health Alliance (EPHA) and he is responsible for the effective implementation of the Health in All Policies legal principle in various EU policies. Zoltán leads EPHA’s ‘Trade for Health’ campaign. A Hungarian qualified lawyer with strong commitment to public interest, he has over 12 years of experience including international and European affairs management matters at the Ministry of Health of Hungary, lawyer-linguist experience at the European Court of Justice, and legal practice at national courts

 

[1] http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2012/pharmaceutical-expenditure_9789264183896-55-en;jsessionid=1qbplkkksa36h.x-oecd-live-03

[2] https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm

[3] https://www.wto.org/english/tratop_e/trips_e/t_agm0_e.htm

[4] https://ec.europa.eu/europeaid/sites/devco/files/communication-eu-role-in-global-health-com2010128-20100331_en.pdf

[5] http://www.unsgaccessmeds.org/list-of-contribution/

[6] http://www.unsgaccessmeds.org/final-report/

[7] http://hepcoalition.org/news/press-releases/article/hepatitis-c-gilead-patent-on-sofosbuvir-partially-maintained-following-mdm

Health Breaking News: Link 256

Health Breaking News Links, as part of the research project PEAH (Policies for Equitable Access to Health), aim to focus on the latest challenges by trade and governments rules to equitable access to health in resource-limited settings

Health Breaking News: Link 256

 

The economic argument against protectionism 

Alternative Financing Strategies to Boost Small Businesses in Africa 

Public-Private Partnerships: Defusing the ticking time bomb 

The right to health and safe abortion in Latin America: still a long way to go 

WHO: Public health round-up 

Most countries lagging on  health SDGs 

Strategic procurement and international collaboration to improve access to medicines 

New MPP-Gilead License For HIV Treatment 

WIPO, Pharma Join Forces To Set Up Database For Medicine Procurers 

California Takes On Drug Pricing: Real Progress Or Illusion? 

Quality Of Medicines A Key Focus Of Antimicrobial Resistance Fight 

WHO Official On AMR: Poor Quality Medicines Entering At “Last Mile” To Patient 

Communicating science-based messages on vaccines 

A Fair Shot for Vaccine Affordability: Understanding and addressing the effects of patents on access to newer vaccines 

Infographic: World Rabies Day – Zero cases by 2030? 

First global pledge to end cholera by 2030 

Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 

Countries urged to take tough action to prevent NCDs 

First Global Funding Pact Launched to Secure Indigenous Land Rights 

Tedros announces WHO senior leadership team 

UNPO Newsletter September 2017 edition 

Gender Equality and Women’s Empowerment in the Arab Region: Where Do We Stand? 

New Ideas to Fight An Old Scourge: Funding Innovation Against Modern Slavery 

European Commission, UN agencies and governments to call for increased social protection for millions of people displaced by protracted crises 

Critical reflections on meaningful youth contributions to global health 

Food supply, nutrition and trade policy: reversal of an import ban on turkey tails 

Community Approaches To Improving Children’s Health: Addressing Childhood Obesity And ACEs In Kentucky 

Big Chickens and McDonald’s Burgers in the Global Spotlight 

Policy options for extending standardized tobacco packaging 

MEPs urge EU to ratchet up climate ambitions ahead of UN summits